Literature DB >> 10074593

Carboplatin-related hematuria and acute renal failure.

M Agraharkar1, S Nerenstone, J Palmisano, A A Kaplan.   

Abstract

Cisplatin is a potent tubular toxin with a high incidence of nephrotoxicity. Carboplatin is considered less nephrotoxic but can still cause tubular injury and interstitial nephritis in patients who have been previously treated with cisplatin. The affected individuals usually have nonoliguric renal failure with a urine output of more than a liter per day. We present a 57-year-old white woman with no history of renal disease who underwent a total abdominal hysterectomy and bilateral salpingo-oophorectomy for stage IC ovarian carcinoma. One month later, she received chemotherapy with paclitaxel (Taxol) and carboplatin. On the following day, she developed frank hematuria and flank pain associated with a diminished urine output. Intravenous pyelogram (IVP) showed bilateral hydronephrosis with a total blockage of dye flow at the level of intraureteral lucencies consistent with bilateral blood clots. Her coagulation profile and uric acid was normal. Her acute renal failure (ARF) spontaneously resolved in the following 24 hours, with a brisk diuresis presumably due to clot lysis. The follow-up IVP showed a resolution of obstructive changes. A review of the literature shows a previous case in which high doses of carboplatin were implicated as the cause of hemorrhagic cystitis, presumably by toxicity to transitional epithelium of the bladder. We believe that the current case represents carboplatin-induced damage to the transitional epithelium in the renal pelvi and ureters causing gross hematuria and blood clots, resulting in bilateral ureteral obstruction and hydronephrosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10074593     DOI: 10.1016/s0272-6386(98)70152-0

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  3 in total

1.  Renal pelvic hemorrhage and acute renal failure associated with carboplatin therapy.

Authors:  Srivilliputtur G Santhana Krishnan; Brian VanderBrink; Gary Weiss; Pravin C Singhal; Hitesh H Shah
Journal:  Urology       Date:  2007-12       Impact factor: 2.649

2.  Nivolumab and ipilimumab therapy in a patient with non-small cell lung cancer with chronic kidney disease.

Authors:  Hiroaki Satoh; Sou Hattori
Journal:  Contemp Oncol (Pozn)       Date:  2022-06-30

3.  Urinary biomarkers for early detection of platinum based drugs induced nephrotoxicity.

Authors:  Mostafa Abdelsalam; Ekramy Elmorsy; Hassan Abdelwahab; Osman Algohary; Mahmoud Naguib; Ahmed Abd El Wahab; Ahmed Eldeeb; Ehab Eltoraby; Adel Abdelsalam; Alaa Sabry; Mohamed El-Metwally; Mohamed Akl; Nahla Anber; Maysaa El Sayed Zaki; Fahad Almutairi; Tamer Mansour
Journal:  BMC Nephrol       Date:  2018-09-04       Impact factor: 2.388

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.